Company Announcements
Portfolio Update
Related Companies
By LSE RNS
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 28 February 2017
|
Net Assets |
£248m |
|
Net Assets per share |
661p |
|
Share price |
590p |
|
Total value of unquoted investments |
£24m |
|
Total number of portfolio companies |
87 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Celgene |
7.6 |
|
Incyte |
7.2 |
|
Biogen |
7.0 |
|
Alexion |
5.3 |
|
Genmab |
4.3 |
|
Amgen |
4.3 |
|
Regeneron |
4.2 |
|
Shire |
4.0 |
|
Illumina |
3.3 |
|
Vertex |
3.2 |
|
|
----------- |
|
Total |
50.4 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
85 |
|
Europe & UK |
15 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
90 |
|
Unquoted |
10 |
|
|
----------- |
|
Total |
100 |
|
NAV % Market Cap |
% NAV |
|
Large Cap >USD10BN |
61 |
|
Mid Cap =USD1-10BN |
19 |
|
Small Cap <USD1BN |
20 |
|
|
----------- |
|
Total |
100 |
|
NAV % by Therapeutic Areas |
% NAV |
|
Oncology |
39 |
|
Orphan |
13 |
|
CNS |
9 |
|
Inflammation |
8 |
|
Ophthalmology |
6 |
|
Medtech |
2 |
|
Other |
23 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
22 MARCH 2017
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN